MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

FASENRA enabled patients to taper off oral corticosteroids while preventing relapses

...

Related Keywords

Japan ,United States ,Washington ,United Kingdom ,Cambridge ,Cambridgeshire ,American ,Sharon Barr ,Michael Wechsler ,International Coordinating Investigator ,Biowa Inc ,Kyowa Kirin Co Ltd ,American Academy Of Allergy Asthma Immunology ,Nasdaq ,Astrazeneca ,Asthma Institute At National Jewish Health ,American Partnership For Eosinophilic Disorders ,New England Journal ,American Academy ,Allergy Asthma ,Annual Meeting ,Birmingham Vasculitis Activity Score ,Asthma Institute ,National Jewish Health ,Executive Vice President ,Asthma Symptoms ,Deteriorating Disease ,Corticosteroid Dosage ,Prescribing Information ,Churg Strauss Syndrome ,Astrazeneca Biopharmaceuticals ,Rare Diseases ,Eosinophilic Granulomatosis ,Breaking Abstracts Presented ,Scientific Sessions ,Meeting February ,Eur Respir ,Allergy Clin ,Zeneca Annual Report ,Zeneca Data ,Very Severe Chronic Obstructive Pulmonary Disease ,Frequent Exacerbations ,Safety Study ,Patients With Hypereosinophilic Syndrome ,